The St. Louis-based biotech hopes to submit an application for its leukemia and lymphoma therapy in 2027, if all goes well in ...

AMX0035 missed the goals of a study in progressive supranuclear palsy. Elsewhere, Novartis and BioArctic struck a deal, and Genentech started building its first East Coast factory.

Stealth secured a new agency review of its experimental therapy elamipretide after a rejection this year. The result could ...

In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior ...

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn ...

Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing ...

Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more ...

The agency said it had become aware of more reports of serious adverse events, leading center director Vinay Prasad to ...

An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which ...

The asset deal thrusts AbbVie to the forefront of the psychedelic field, handing it a therapy that recently scored positive ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...